Pascal FURET

BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER

BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS

INTERLEUKIN-17 INHIBITORS

Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors

OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS

Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Formylated N-heterocyclic derivatives as FGFR4 inhibitors

Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors

USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

Formylated N-heterocyclic derivatives as FGFR4 inhibitors

Pharmaceutical combinations

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Compounds

Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors

Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction

Substituted purinone compounds

Use of inhibitors of the activity or function of PI3K

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

Pharmaceutical diagnostic

Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension

Oxazolidin-2-one compounds and uses thereof

Pyrazolopyrrolidine compounds

COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1

IMIDAZOPYRROLIDINONE COMPOUNDS

Purine derivatives and their use in the treatment of disease

Cyclohexyl isoquinolinone compounds

Salt forms of bicyclic heterocyclic derivatives

Quinazoline Derivatives

PYRROLIDINE-1,2-DICARBOXAMIDE DERIVATIVES

Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases

Hydroxy substituted isoquinolinone derivatives

Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases

Pyrrolidine-1,2-dicarboxamide derivatives

1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES

Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors

Pyrrolopyrrolidinone compounds

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Substituted isoquinolinones and quinazolinones

Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension

Oxazolidin-2-one compounds and uses thereof

Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES

PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES

Pyrirnidinyl aryl urea derivatives being FGF inhibitors

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors

Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors

Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls

Pyrrolidine-1,2-dicarboxamide derivatives

Imidazoquinolines as lipid kinase inhibitors

PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS

ETHER DERIVATIVES OF BICYCLIC HETEROARYLS

TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS

BICYCLIC AMIDES AS KINASE INHIBITORS

1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors

INHIBITORS OF TYROSINE KINASES

3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives

Substituted 2-carboxamide cycloamino ureas

Pyrrolidine-1,2-dicarboxamide derivatives

3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases

Phenylacetamides being FLT3 inhibitors

Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors

1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors

Heterocyclic compounds as antiinflammatory agents

Lck inhibitors

IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS

Inhibitors of tyrosine kinases

3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors

DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS

2,4-Substituted Quinazolines as Lipid Kinase Inhibitors

Compounds and compositions as protein kinase inhibitors

DISUBSTITUTED UREAS AS KINASE INHIBITORS

3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors

Organic compounds

INHIBITORS OF HSP90

Inhibitors of HSP90

Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors

Phenylacetamides suitable as protein kinase inhibitors

Pyrimidinyl aryl urea derivatives being FGF inhibitors

Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors

Bicyclic amides as kinase inhibitors

3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors

1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors

Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors

Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors

2-cyano-pyrimidines and-triazines as cysteine protease inhibitors

1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors

Inhibitors of tyrosine kinases

Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors